Cullinan Therapeutics, Inc.
CGEM Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$14.54
KIRA · Stoqly’s AI analyst, in plain words
- Cullinan Therapeutics, Inc. lost $220M in fiscal 2025.
- Free cash flow was −$176M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
—
Net income
−$220M
Free cash flow
−$176M
Operating margin
—
Cullinan Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$220M
No. It lost money last year.
What Cullinan Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Cullinan Therapeutics, Inc.
- CIK
- 0001789972
Cullinan Therapeutics, Inc. · CGEM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $18.9M | $0.0M | — | — | — |
| Revenue growth | — | −100.0% | — | — | — |
| Operating margin | −358.7% | — | — | — | — |
| Net income | −$65.6M | $111M | −$153M | −$167M | −$220M |
| Net margin | −346.1% | — | — | — | — |
| Diluted EPS | −$1.52 | $2.38 | −$3.69 | — | — |
| Cash | |||||
| Cash from operations | −$43.4M | −$127M | −$134M | −$145M | −$176M |
| Capital expenditure | $0.0M | $1.1M | $0.2M | $0.0M | $0.0M |
| Free cash flow | −$43.4M | −$128M | −$134M | −$145M | −$176M |
| FCF margin | −229.3% | — | — | — | — |
| Share count change | 116.6% | 8.3% | −10.9% | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $290M | $467M | $467M | $399M | $378M |
| Shareholders' equity | $425M | $535M | $454M | $590M | $409M |
| Current ratio | 25.2x | 21.1x | 17.1x | 13.5x | 10.2x |
| Returns and quality | |||||
| Return on equity | −21.0% | 23.2% | −31.0% | −32.1% | −44.0% |
| Return on tangible equity | −15.4% | 20.8% | −33.8% | −28.4% | −53.8% |
| Piotroski F-score | 4 | 2 | — | — | — |
| Altman Z'' | 39.8 | 28.3 | 17.8 | 19.7 | 8.0 |
Insiders bought, 12 months
$1.4M
1 insider
Insiders sold, 12 months
$2.5M
5 insiders
Of sales under plans
63%
$1.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cullinan Therapeutics, Inc. · CGEM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $14.54 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001789972). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.